Axsome Therapeutics, Inc. (AXSM)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Developing and Delivering novel therapies for the management of CNS disorders	638.50M	385.69M	270.60M	50.04M	-
Developing and Delivering novel therapies for the management of CNS disorders Growth	65.55%	42.53%	440.80%	-	-
Total	638.50M	385.69M	270.60M	50.04M	-
Total Growth	65.55%	42.53%	440.80%	-	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	628.62M	378.16M	197.22M	49.13M	-
United States Growth	66.23%	91.74%	301.42%	-	-
Outside of The United States	9.88M	7.53M	73.38M	905.00K	-
Outside of The United States Growth	31.13%	-89.73%	8007.85%	-	-
Total	638.50M	385.69M	270.60M	50.04M	-
Total Growth	65.55%	42.53%	440.80%	-	-

Data Source: S&P Global Market Intelligence Last updated: May 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 11, 2026

Data Sources Report a data error